• Home
  • Programs
  • News
  • Publications
  • Team
  • Contact
Talk To Us
All articles

Durability depends on tissue type

Published
2 Nov 2026
Reading time
7 min
Series
The Science Behind RT-100
Program
RT-100

Alan Horsager, PhD

President and CEO

Share

Summary

RT-100 uses an adenoviral vector, and adenoviral vectors are known for short-lived gene expression. The heart is an exception. Heart muscle cells don't divide, and they appear to be poor at flagging themselves for immune attack, so a gene delivered to the heart can persist well past the window typical of other tissues. In pigs, a single intracoronary treatment produced AC6 activity in the heart that was still elevated 18 weeks later. That window comfortably contains the 12 weeks over which improvement was measured in patients.

Ask anyone who works in gene therapy about adenovirus and you'll hear the same thing: it gets genes into cells efficiently, but the effect doesn't last. Expression peaks within about a week and is largely gone within a month. That reputation is well earned, and it's the first question a thoughtful investor or cardiologist asks about RT-100, which uses an adenoviral vector to deliver the gene for adenylyl cyclase type 6 (AC6) to the heart.

It's the right question. The answer is that durability is not a property of the vector alone. It depends on the tissue the vector is delivered to, and the heart behaves differently from the tissues that gave adenovirus its reputation.

Why adenoviral expression usually fades

A gene therapy vector is a delivery vehicle. It carries a therapeutic gene into a cell, where the gene sits alongside the cell's own DNA as a separate, free-floating loop and is read to make protein. Neither adenovirus nor AAV, the other common gene therapy vector, permanently inserts its cargo into the chromosome in any meaningful way. So the difference in how long the two last isn't about the stability of the DNA itself.

Much of it comes down to the immune system. An AAV vector carries almost nothing beyond the therapeutic gene. An adenoviral vector like RT-100 has had the genes it needs to replicate removed, but it still carries other viral genes, and a transduced cell makes small amounts of those viral proteins. The cell then does what cells are built to do with foreign protein: it chops it into fragments and displays them on its surface. Most adults have encountered adenovirus type 5 at some point, often as a childhood respiratory infection, so their immune systems already carry T cells primed to recognize those fragments. Those T cells find the display and destroy the cell, and the therapeutic gene goes with it.

That's the mechanism behind the familiar four-week figure. AAV isn't immunologically invisible either; immune responses to its shell and its cargo are well documented in patients1. But four weeks is a general default rather than a rule. How long expression lasts depends on the tissue, the dose, the route, and the host.

Why the heart is different

There are two independent reasons heart muscle may hold onto an adenoviral gene longer than other tissues.

Heart muscle cells don't divide. A free-floating loop of DNA isn't copied when a cell divides, so in tissues where cells turn over, such as the liver, the gene is gradually diluted away. Adult heart muscle cells are essentially permanent, renewing at well under one percent a year. Once a gene is in, there is no dilution working against it. The Phase 2 publication makes this point directly2.

Heart muscle cells are relatively poor at flagging themselves for attack. To be recognized by a T cell, a cell has to process the viral protein internally and move the fragments to its surface. Researchers studying human cardiac muscle cells found that the display machinery itself works normally: when a viral fragment was loaded onto the cells from outside, T cells recognized and killed them. But when the cells had to process a viral protein from the inside, the same T cells largely failed to recognize them. The reason was lower levels of several components of the internal processing pathway3.

We want to be careful about how far that finding goes. The study used a cardiac cell line and a different virus, not adenovirus in a living heart, and the heart is certainly not walled off from the immune system. It contains resident immune cells and can mount a vigorous response to viral infection. The narrower point is that heart muscle cells appear to be weaker at one specific step, and it happens to be the step RT-100's residual viral proteins would need to pass through to trigger clearance.

What about prior exposure to adenovirus?

If most adults already carry immunity to adenovirus type 5, a reasonable worry is that the therapy would be neutralized before it ever reached the heart. We were able to test that directly. In the Phase 2 trial, every participant's level of pre-existing antibody against the vector was measured before treatment. Levels ranged from undetectable to very high, and they showed no relationship with how patients responded, at either 4 weeks or 12 weeks2. Earlier large-animal work pointed the same way. Pigs deliberately immunized against the vector beforehand, then given a related intracoronary adenoviral therapy, still showed the therapeutic effect, with no increase in inflammation5.

That answers part of the question, not all of it. Antibodies determine whether the vector reaches its target. T cells determine how long a transduced cell survives, and T-cell responses weren't measured in the trial. Pre-existing immunity clearly didn't prevent a response, but it remains an area for further study.

What the data show

The clearest evidence comes from pigs. A single intracoronary dose of an adenoviral vector carrying AC6, an earlier version of the vector built with the mouse gene, raised the heart's capacity to generate cAMP, which is the biochemical signature of AC6 activity. Two weeks after treatment that capacity had roughly doubled, and it was still elevated at 4, 8, 12, and 18 weeks, the last timepoint measured4.

Figure 1

Durability: the gene keeps working for months (pig)

cAMP-generating capacity as a multiple of control (1.0 = control) · up = gene still working.

cAMP-generating capacity after a single dose, in pigsAs a multiple of the normal (control) level: 2.0 at 2w, 2.4 at 4w, 1.8 at 8w, 1.6 at 12w, 1.7 at 18w. A shaded band marks the first 4 weeks, the window in which adenoviral expression is typically reported.Window in whichadenoviralexpression istypically reported3.02.01.00normal (control) levelcAMP capacity× control · up = still working2w4w8w12w18w2.02.41.81.61.71.7×
  • Single dose (n=4-6)
  • Control level (1.0)

Statistics

p<0.0002 vs control, all time points

RT-100 is given only once, so the key question is whether its effect lasts. In pigs, a single intracoronary dose kept forskolin-stimulated cAMP production — a biomarker for AC6 activity — between about 1.6 and 2.4 times above control for at least 18 weeks, roughly four months, with no sign of fading. Eighteen weeks was the last time point measured, not the point at which the effect ended. This is the published basis for RT-100's one-time design.

Source: Lai et al., Circulation 2000;102:2396, Figure 3C. Error bars not supplied in the copy.

The effect on the heart's pumping function tracked the same way. It appeared six days after treatment and was undiminished at 57 days, which is where that measurement stopped. The reason it stopped is worth knowing: the implanted pressure sensor used to record it has a service life of about two months. The measurement ran out before the effect did.

This is the study the Phase 2 publication cites when it addresses durability.

What it means for patients

This is where it's easy to claim more than the evidence supports, so we'll be precise.

In the Phase 2 trial, heart function was measured at 4 and 12 weeks after treatment. Patients in the highest-dose groups showed improved ejection fraction, with the clearest response in patients with non-ischemic heart failure, and catheter measurements showed improved relaxation of the heart muscle at 4 weeks. Over a full year, 9.5 percent of treated patients were hospitalized for heart failure compared with 28.6 percent of patients given placebo. That is an encouraging difference, but the trial was too small to confirm it statistically2.

So the question that actually needs explaining is not how a benefit could last a year on an adenoviral vector. It's how the benefit lasts through 12 weeks, and the preclinical data already answer that. Twelve weeks falls well inside the window in which AC6 activity has been shown to persist in the heart.

What we still need to learn

Several questions remain open, and the next study is designed to address them. We want to understand how long the benefit lasts in patients beyond 12 weeks, measured directly and repeatedly. We want to know whether cellular immunity to adenovirus affects how long treated heart cells survive.

And there is an intriguing possibility that some of AC6's effects could outlast the gene itself. One of the ways AC6 improves calcium handling is by reducing the cell's production of phospholamban, a natural brake on the heart's calcium pump, through a change in how that gene is transcribed rather than a temporary chemical modification of protein already present6. Notably, several of AC6's benefits persist even with a version of the enzyme that cannot generate cAMP at all, so the mechanism is broader than the signaling pathway alone7. Whether a transcriptional change of this kind holds after AC6 levels fall has never been tested. Just an idea, but a testable one.

Durability is the right question to ask of any adenoviral therapy. For RT-100, the answer starts with the biology of the heart itself.

RT-100 is an investigational therapy. It has not been approved by the FDA or any other regulatory agency and is available only within clinical trials.

References

  1. 1. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23–36. DOI
  2. 2. Hammond HK, Penny WF, Traverse JH, Henry TD, Watkins MW, Yancy CW, et al. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial. JAMA Cardiol. 2016;1(2):163–171. DOI
  3. 3. Sundstrom JB, Jollow KC, Braud V, Villinger F, McMichael AJ, Lawrence EC, Ades EW, Ansari AA. Magnitude of alloresponses to MHC class I/II expressing human cardiac myocytes is limited by their intrinsic ability to process and present antigenic peptides. Clin Dev Immunol. 2003;10(2–4):213–226. DOI
  4. 4. Lai NC, Roth DM, Gao MH, Fine S, Head BP, Zhu J, McKirnan MD, Kwong C, Dalton N, Urasawa K, Roth DA, Hammond HK. Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation. 2000;102(19):2396–2401. DOI
  5. 5. Roth DA, McKirnan MD, Canestrelli I, Gao MH, Dalton N, Lai NC, Roth DM, Hammond HK. Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus. Hum Gene Ther. 2006;17(2):230–238. DOI
  6. 6. Gao MH, Tang T, Guo T, Sun SQ, Feramisco JR, Hammond HK. Adenylyl cyclase type VI gene transfer reduces phospholamban expression in cardiac myocytes via activating transcription factor 3. J Biol Chem. 2004;279(37):38797–38802. DOI
  7. 7. Gao MH, Tang T, Lai NC, Miyanohara A, Guo T, Tang R, Firth AL, Yuan JXJ, Hammond HK. Beneficial effects of adenylyl cyclase type 6 (AC6) expression persist using a catalytically inactive AC6 mutant. Mol Pharmacol. 2011;79(3):381–388. DOI

Related news

All news and articles
  • Company News2 Nov 2026

    Renova assembles the team for RT-100's next trial

    Read the News
  • Science Series2 Nov 2026

    Fit-for-purpose delivery decreases risk

    Read the News
Renova Therapeuticsinfo@renovagtx.com
Pasadena, California
  • Home
  • Programs
  • News
  • Publications
  • Team
  • Contact
  • LinkedIn
  • X
Sources
  1. 01

    American Heart Association. 2026 Heart Disease and Stroke Statistics Update. Link

  2. 02

    Gorodeski EZ et al. HF STATS 2026: An Updated Report on Heart Failure Epidemiology and Outcomes from the Heart Failure Society of America. J Card Fail. 2026. DOI

  3. 03

    Hammond HK et al. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial. JAMA Cardiol. 2016;1(2):163–171. DOI

  4. 04

    Penny WF, Hammond HK. Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction. Hum Gene Ther. 2017;28(5):378–384. DOI

© 2026 Renova Therapeutics, Inc.

  • Privacy Policy
  • Terms of Use